Basic Information
Cystagon
Regulatory Information
EMEA/H/C/000125
June 23, 1997
20
December 11, 2024
Company Information
France
Immeuble le Wilson 70, avenue du Général de Gaulle 92800 Puteaux
RECORDATI RARE DISEASES
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Cystagon is indicated for the treatment of proven nephropathic cystinosis. Cysteamine reduces cystine accumulation in some cells (e.g. leukocytes, muscle and liver cells) of nephropathic cystinosis patients and, when treatment is started early, it delays the development of renal failure.
Overview Summary
This is a summary of the European public assessment report (EPAR) for Cystagon. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Cystagon.